Tower Research Capital LLC TRC Boosts Holdings in Grifols, S.A. (NASDAQ:GRFS)

Tower Research Capital LLC TRC increased its holdings in Grifols, S.A. (NASDAQ:GRFS) by 354.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,124 shares of the biotechnology company’s stock after purchasing an additional 6,335 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Grifols were worth $60,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. R Squared Ltd purchased a new position in shares of Grifols in the fourth quarter valued at about $28,000. GAMMA Investing LLC raised its holdings in shares of Grifols by 44.5% during the fourth quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 1,527 shares in the last quarter. Blue Trust Inc. increased its position in Grifols by 254.0% during the 4th quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 4,970 shares during the period. First Trust Advisors LP purchased a new stake in shares of Grifols in the 4th quarter worth about $75,000. Finally, Envestnet Portfolio Solutions Inc. bought a new position in Grifols in the fourth quarter worth about $77,000.

Wall Street Analyst Weigh In

Separately, Morgan Stanley started coverage on Grifols in a research report on Wednesday, February 12th. They set an “overweight” rating for the company.

Grifols Price Performance

Shares of NASDAQ GRFS opened at $7.15 on Monday. The firm has a market cap of $4.92 billion, a P/E ratio of 6.11 and a beta of 0.44. The company has a 50 day moving average of $7.34 and a 200 day moving average of $7.65. Grifols, S.A. has a twelve month low of $5.79 and a twelve month high of $9.96. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.